Business
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
- Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio - Expands
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\n- Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio\n\n\n- Expands portfolio with PBGENE-PMM as a potentially curative treatment for primary mitochondrial myopathy\n\n\n- Virtual R&D Day featuring key opinion leaders and members of Precision’s leadership and scientific teams to be held today at 9:00 AM ET\n\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET.\n\n\n“At Precision, we are moving forward with a renewed identity and focus on our core foundational strength as a gene editing company. During today’s R&D Day, we are excited to highlight the potential of our ARCUS genome editing platform to develop differentiated programs enabled by the nature of ARCUS’ unique cut, size, and simplicity,” said Michael Amoroso, Chief Executive Officer at Precision BioSciences. “In addition to illustrating where we see a clear advantage for ARCUS, we will drill down on the novel attributes of ARCUS that inform our development program strategy. We look forward to highlighting the progress we are making across our robust wholly-owned and partnered in vivo gene editing portfolio.”\n\n\n“As we continue advancing our lead program PBGENE-HBV targeting hepatitis B virus (HBV) toward a 2024 clinical trial application (CTA) and/or investigational new drug (IND) application, we are pleased to introduce PBGENE-PMM, our first development candidate targeting mitochondrial DNA. PBGENE-PMM holds the potential to deliver a one-time, transformative treatment for patients with primary mitochondrial myopathy (PMM),” said Jeff Smith, Co-Founder and Chief Research Officer. “Together with PBGENE-HBV, we believe that both of these programs are emblematic of the unique advantages of our ARCUS technology. As we look ahead, we plan to drive organic development of programs focusing on more sophisticated edits such as viral or mutant mitochondrial genome elimination, defective gene excision, and gene insertion with ARCUS, while also...